# Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

> **NCT04529278** · PHASE2 · UNKNOWN · sponsor: **Fondation Hôpital Saint-Joseph** · enrollment: 18 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Hemodialysis
- Obese

## Interventions

- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT04529278
- **Lead sponsor:** Fondation Hôpital Saint-Joseph
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-18
- **Primary completion:** 2023-01-17
- **Final completion:** 2023-12-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04529278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04529278, "Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT04529278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*